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Abstract
Background Opioid abuse and dependence is problematic
across many age groups, including the working-age popu-
lation and their dependents. Little is known, however,
about the economic costs of opioid abuse/dependence
imposed on employers, who pay for a substantial portion of
healthcare costs through their contributions to employer-
sponsored health insurance and are also affected by indirect
costs such as those due to disability and workplace
absenteeism.
Objective To provide a comprehensive, current estimate
of the economic burden of prescription opioid abuse/
dependence to employers.
Methods Administrative claims from beneficiaries cov-
ered by large self-insured companies throughout the USA
were used to identify patients, including employees and
dependents, who were diagnosed with opioid abuse and/or
dependence (‘abusers’) between 2006 and 2012. Health-
care and work-loss costs for abusers were assessed over a
12-month period and compared with those for patients not
diagnosed with abuse (‘comparison patients’), using pro-
pensity score matching.
Results 7,658 matched pairs of abusers and comparison
patients were analysed. Relative to comparison patients,
abusers had significantly higher annual healthcare resource
utilization, leading to US$10,627 in per-patient
incremental annual healthcare costs. Additionally, abusers
had US$1,244 in excess annual work-loss costs. Together,
this implies an employer burden for diagnosed abuse of
US$1.71 per member per month.
Conclusion Opioid abuse/dependence impose a sub-
stantial economic burden on employers.
Key Points for Decision Makers
Diagnosed opioid abuse/dependence results in
substantial excess healthcare and work-loss costs
The prevalence of diagnosed opioid abuse/
dependence has increased from 2006 to 2012
1 Introduction
1.1 Background
Pain is a highly prevalent condition. The Institute of
Medicine estimates that over 100 million US adults suffer
from chronic pain due to medical conditions, such as
arthritis, back pain, migraine headaches and postoperative
pain [1]. Many of these conditions affect mental and
physical functioning, often severely restricting the ability
to perform daily routines [2]. To treat pain, physicians
have increasingly turned to prescription opioid analgesics,
which are among the most effective drugs for pain man-
agement [3]. As a result, opioids have become some of the
most frequently prescribed medications in the USA, with
over 235 million prescriptions dispensed in 2011,
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corresponding to US$8.3 billion in sales [4]. These medi-
cations, however, also carry the risk of potential abuse,
unintended misuse and dependence. According to the
National Survey on Drug Use and Health (NSDUH), the
number of Americans who abused or were dependent upon
pain relievers increased from 1.6 to 1.8 million between
2006 and 2011 [5, 6]. The NSDUH is a primary source of
information on the use of illicit drugs, alcohol and tobacco
in the civilian, non-institutionalized population of the USA
aged 12 years or older, and questions about illicit drug and
alcohol dependence and abuse are based on criteria in the
Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV). In order to be consistent with the
NSDUH, we combine opioid abuse and dependence in this
article. For simplicity, throughout this manuscript, we use
the term ‘abuse’ to describe the combination of abuse and
dependence.
Opioid abuse is problematic across many age groups,
including the working-age population and their depen-
dents [7]. For those individuals, employers pay for a sub-
stantial portion of healthcare costs through their
contributions to employer-sponsored health insurance, and
they are additionally impacted by indirect costs such as
those due to disability and workplace absenteeism.
Although opioid abuse has received widespread public
attention in recent years, little is known about the economic
costs of opioid abuse from an employer perspective.
The limited research that exists on the economic costs of
opioid abuse suggests that these costs can be substantial for
employers [8–10]. For example, Birnbaum et al. [8] esti-
mated that, on a societal level, opioid abuse imposes an
annual economic burden of US$55.7 billion, with nearly
half (US$25.6 billion) of that total being due to workplace
costs. In addition, using 2003–2007 data on commercially
insured patients, White et al. [9] estimated that the average
per-patient annual healthcare costs of patients diagnosed
with abuse exceeded those of a comparison population by
over US$20,000. Those studies, however, used relatively
few adjustments to control for a variety of potential dif-
ferences between abusers and comparison patients. For
example, it has been found that mental health conditions
are both highly prevalent and associated with increased
medical costs among abusers, and it is unclear to what
extent the cost differentials found in those prior analyses
were driven by abuse versus other underlying conditions
that are disproportionately prevalent among abusers [11,
12]. In addition, the data used in those analyses pre-dated
widespread private and public efforts to increase awareness
of and reduce prescription opioid abuse and, as a result,
they likely reflected neither the current prevalence of
diagnosed abuse, which has increased nearly threefold over
the 5-year period from 2006 to 2011 (Fig. 1), nor current
abuse-related costs.
The objective of this study was to improve upon pre-
vious research by providing a more refined, current esti-
mate of the excess healthcare and work-loss costs of
prescription opioid abuse among commercially insured
patients from 2006–2012. Excess costs of abuse were
assessed using a study design that accounted for potential
differences in age, sex, comorbidities and healthcare
resource use between abusers and comparison patients.
Annual incremental abuse-related costs, including health-
care and work-loss costs due to disability and medically
related absenteeism, were calculated from the perspective
of a self-insured employer.
2 Methods
2.1 Data
This study used de-identified administrative claims data
from OptumHealth Reporting and Insights, a database
containing information on approximately 16 million com-
mercially insured beneficiaries (employees, spouses, chil-
dren and retirees) from 60 large self-insured companies
with locations across the USA, and representing a variety
of industries and job types. The data included medical
claims (dates of service, diagnoses received, procedures
performed, places of service and payment amounts),
pharmacy claims (fill dates, national drug codes [NDCs]
and payment amounts), and eligibility information (patient
demographics, enrolment history and wage information)
for all beneficiaries for the period January 1999–March
2012. Data reporting work loss due to short- and long-term
disability were available for employees from 33 of the 60
companies.
2.2 Sample Selection
Two mutually exclusive cohorts of commercially insured
beneficiaries—including primary beneficiaries (i.e.
employees) and dependents—were selected. Patients with
abuse were identified as those with at least one of the
following International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes for
opioid abuse or dependence during the period January
2006–March 2012: 304.0x, 304.7x, 305.5x, 965.00, 965.02
and 965.09 [7]. As mentioned above, our use of both opi-
oid abuse and dependence diagnosis codes is consistent
with the NSDUH, which combines prescription pain
reliever abuse and dependence [5]. This is also consistent
with the Diagnostic and Statistical Manual of Mental
Disorders, 5th edition (DSM-V), which combines catego-
ries of substance abuse and substance dependence into a
single disorder [13]. In addition, clinical input suggests
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that opioid abuse and dependence diagnosis codes are often
used interchangeably on insurance claims. A prior study on
the excess costs of opioid abuse found that the magnitude
of the excess costs was similar regardless of whether
abuse-only or dependence-only codes were used [14].
Several other studies on opioid abuse have also used both
opioid abuse and dependence diagnosis codes [7–9, 15].
Therefore, our cohort of ‘abusers’ contained patients
diagnosed with abuse and/or dependence.
Because the objective of the analysis was to assess
recent costs of abuse, patients with an abuse diagnosis prior
to 2006 were excluded. The cohort of potential comparison
patients was defined as all patients who did not have any of
the aforementioned opioid abuse diagnoses at any time in
their claims history (i.e. January 1999–March 2012).
Because this resulted in a large comparator population, a
10 % random sample was used for estimation purposes.
For abusers, the index date was defined as the date of the
first abuse diagnosis. For the comparison patients, the index
date was assigned as the date of a random medical claim.
Each individual was observed over a 12-month follow-
up period, which was centred on the index date and
included the 6-month period prior to the index date, as
abuse may result in medical costs prior to a formal diag-
nosis of abuse. This follow-up period was preceded by a
6-month baseline period, which was used for propensity
score matching. Patients were required to be aged
12–64 years and continuously eligible with non-Health
Maintenance Organization (non-HMO) coverage through-
out the 18-month study period to ensure that all relevant
drug and medical claims were captured for the final sample
of patients. Patients aged 65 years and older were excluded
from our study, as their Medicare eligibility may have
limited our ability to observe all relevant drug and medical
claims. These selection criteria resulted in a final analytic
sample of 9,291 abusers and 395,901 comparison patients
(Fig. 2).
2.3 Prevalence of Diagnosed Abuse
The prevalence rate of diagnosed abuse was calcu-
lated for each year from 2006 to 2011. The prevalence
rate of diagnosed abuse in a given year was calculated as
the proportion of covered lives (aged 12–64 years) with
at least 1 month of eligibility in the calendar year
that had at least one diagnosis for opioid abuse in that
year.
2.4 Propensity Score Matching
Propensity score matching was used to account for obser-
vable differences at baseline between abusers and com-
parison patients. Propensity scores were estimated using
logistic regression for all abusers and potential comparison
patients on the basis of sex, age, US Census Division,
selected baseline comorbidities that are likely to affect
healthcare costs (e.g. cancer, congestive heart failure,
mental health disorders) and baseline healthcare resource
utilization (e.g. days hospitalized, days with an emergency
department [ED] visit, prescription drug use). In order to
ensure that patients were matched to those with availability
of comparable treatment options and to facilitate the
healthcare and work-loss cost comparisons, abusers were
matched one-to-one with comparison patients on the basis
of the year of the index date, baseline healthcare costs
(±10 %), availability of work-loss data and propensity
score (within a quarter of a standard deviation [SD]), using
greedy matching [16]. Full details of propensity score
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Fig. 1 Estimated prevalence of
opioid abuse in the
OptumHealth commercial
claims database. The presence
of diagnosed opioid use/
dependence was measured in
the claims data as the proportion
of covered lives (ages
12–64 years) with at least
1 month of eligibility in the
calendar year that had at least
one diagnosis for opioid use/
dependence in that year
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2.5 Outcomes
Total and incremental all-cause healthcare resource use and
costs (as measured by payments made by third-party pay-
ers) in the 12-month follow-up period were compared for
both abusers and comparison patients. Resource use and
costs were categorized by the place of service (i.e. an
inpatient facility, ED, outpatient/physician’s office, reha-
bilitation facility, other [e.g. skilled nursing facility]) in
order to understand the extent to which different types of
healthcare resource utilization contribute to the cost dif-
ferential between abusers and comparison patients. In
addition, incremental indirect work-loss costs due to dis-
ability and medically related absenteeism were estimated
for the subset of commercially insured patients for whom
disability and wage information was available. For those
patients, information regarding days and costs of missed
work due to medical visits and/or disability were obtained
directly from the database. Following Birnbaum et al. [8],
medically related absenteeism was estimated by multiply-
ing the number of days with medical resource use by the
employee’s wage: each ED visit accounted for a full day of
missed work, the number of days hospitalized accounted
for the equivalent number of full days of missed work and
all other visits accounted for half a day of missed work
each. This methodology for estimating medically related
absenteeism has been used in other published studies
estimating indirect work-loss costs [17, 18]. All costs were
inflated to 2012 US dollars, using the Consumer Price
Index [19].
Costs were also expressed in per-member per-month
(PMPM) costs (which are sometimes referred to as ‘per-
person per-month’ costs). The excess PMPM healthcare
costs were calculated as the product of the prevalence of
diagnosed opioid abuse and the per-patient excess health-
care costs. Similar calculations were conducted for the
excess PMPM work-loss costs associated with diagnosed
opioid abuse among individuals who were primary bene-
ficiaries (as the work-loss costs of family members are not
borne by a primary beneficiary’s employer).
2.6 Statistical Analyses
For categorical variables, statistical significance was
assessed using v2 tests (pre-match) and McNemar tests
(post-match). For continuous variables, statistical signifi-
cance was assessed using Wilcoxon rank-sum tests (pre-
match) and Wilcoxon signed-rank tests (post-match). In
Fig. 2 Sample selection.
HMO Health Maintenance
Organization, Q1 quarter 1
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addition, differences in mean costs post-matching were
also evaluated using matched t tests. Confidence intervals
(CIs) were calculated using the means and standard errors
of the reported statistics.
3 Results
3.1 Prevalence of Diagnosed Abuse
In 2011, the most recent year for which a full year of
claims data were available, the prevalence of diagnosed
abuse was 18.6 per 10,000 (95 % CI 18.2–19.1 per 10,000)
[Fig. 1]. There was a steady increase in the prevalence of
diagnosed opioid abuse from 2006 (6.7 per 10,000,
95 % CI 6.4–6.9 per 10,000) to 2011.
3.2 Pre-match Baseline Characteristics
Table 1 compares baseline characteristics between the abusers
and comparison patients before and after matching. Before
matching, abusers were statistically different (p \ 0.001) from
comparison patients on all demographic measures, with
abusers being more likely to be male (54.5 versus 47.4 %;
p \ 0.001) and having different age and geographic distribu-
tions. There were also significant differences in the pre-match
comorbidity profile and healthcare resource utilization for
abusers and comparison patients. Specifically, the average
Charlson Comorbidity Index (a score used to assess the general
comorbidity burden) among abusers was over 80 % higher
than that of comparison patients (0.33 [SD 0.9] versus 0.18
[SD 0.6]; p \ 0.001), with abusers having at least twice the
prevalence rate of comparison patients on 11 of the 17 con-
ditions included in the index [20]. In addition, abusers were
substantially more likely to have been diagnosed with abuse of
other non-opioid substances (9.6 versus 0.9 %; p \ 0.001),
psychotic disorders (16.2 versus 2.7 %; p \ 0.001) or other
mental health disorders (27.7 versus 7.2 %; p \ 0.001) in the
baseline period.
As a result, abusers used significantly more healthcare
resources, on average, in the baseline period, including days in
an inpatient facility (1.0 day [SD 5.1] versus 0.1 days [SD 1.7];
p\0.001) and ED (1.0 day [SD 3.5] versus 0.2 days [SD 1.1];
p\0.001). These differences resulted in average baseline
healthcare costs among abusers being nearly four times those of
comparison patients (US$8,418 [SD US$25,390] versus
US$2,129 [SD US$9,503]; p\0.001).
3.3 Post-match Follow-Up Period Resource
Use and Costs
Of the 9,291 abusers who met the initial selection criteria,
the matching process resulted in identification of 7,658
matched pairs of abusers and comparison patients that were
well balanced with respect to the baseline characteristics
discussed above.
Despite having well-balanced baseline characteristics
post-matching, abusers had significantly higher healthcare
resource use and costs during the 12-month follow-up period
(Table 2). Specifically, abusers spent an average of 6.2 more
days in a drug rehabilitation facility and had, on average, 3.6
more days of hospitalization (?491 %), 1.7 more ED visits
(?310 %) and 5.3 more outpatient/physician office visits
(?137 %) annually, compared with matched comparison
patients. The average annual per-patient healthcare costs of
abusers were US$20,343 (SD US$36,498), compared with
US$9,716 (SD US$26,676) for matched comparison
patients, yielding excess costs of US$10,627 (95 % CI
US$9,665–US$11,590).The main driver of the excess cost
differential was inpatient costs, which accounted for
approximately one third (US$3,498) of the cost differential,
followed by ED costs (US$2,291) and rehabilitation facility
costs (US$1,772).
Among the subset of patients for whom work-loss data
were available, abusers also missed significantly more work
because of disability or medically related absenteeism dur-
ing the follow-up period than matched comparison patients
(Table 3), with an average of 6.3 more days on disability
leave (15.5 [SD 51.7] versus 9.2 [SD 36.3]; p = 0.002) and
7.0 more days lost because of medically related absenteeism
(13.4 [SD 19.3] versus 6.4 [SD 7.2]; p \ 0.001), for a total
of 13.3 more days of missed work annually, on average. The
average annual per-patient indirect work-loss costs, which
included both disability and medically related absenteeism
costs, were US$3,773 (SD US$6,648) for abusers and
US$2,528 (SD US$4,612) for matched comparison patients,
yielding excess indirect work-loss costs of US$1,244
(95 % CI US$790–US$1,699).
Applying the 2011 prevalence of diagnosed opioid
abuse (18.6 per 10,000) [Fig. 1] to the excess healthcare
and work-loss costs discussed above, we estimated the
costs of diagnosed opioid abuse from an employer per-
spective to be US$1.71 PMPM, with US$1.65 of that total
comprising healthcare costs alone. In combining the
healthcare and work-loss costs, it was necessary to account
for the fact that not all covered beneficiaries were actively
employed by the employer throughout the study period.
The average portion of the year during which beneficiaries
were employed (31 %) was used to scale down work-loss
costs.
4 Discussion
Employers may not be aware of the substantial burden that
opioid abuse imposes on them. The analyses described
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Table 1 Demographics, comorbidities and medical resource use in the baseline perioda
Unmatched sample Matched sampleb
Abusers Comparison
patients
p valuec Abusers Comparison
patients
p valued
% N % N % N % N
All patients 100 % 9,291 100 % 395,901 – 100 % 7,658 100 % 7,658 –
Age in years at index date [mean]
(SD)
[37.4] (14.6) [40.0] (15.5) \0.001 [36.5] (14.6) [37.0] (16.3) 0.015
Male sex 54.5 % 5,063 47.4 % 187,705 \0.001 56.4 % 4,321 54.7 % 4,186 0.013
US Census Division
East North Central 19.3 % 1,795 17.4 % 68,703 \0.001 18.6 % 1,425 20.5 % 1,573 0.001
Middle Atlantic 18.4 % 1,706 14.5 % 57,456 \0.001 18.7 % 1,435 19.2 % 1,473 0.398
South Atlantic 17.6 % 1,639 18.9 % 74,902 0.002 18.3 % 1,398 16.7 % 1,279 0.007
West South Central 10.4 % 966 13.3 % 52,497 \0.001 10.3 % 792 10.0 % 767 0.482
Mountain 9.5 % 887 7.3 % 28,950 \0.001 9.3 % 709 9.5 % 730 0.528
Pacific 8.2 % 763 9.2 % 36,386 0.001 8.0 % 612 7.6 % 579 0.291
East South Central 7.4 % 685 5.5 % 21,793 \0.001 7.5 % 575 7.0 % 536 0.192
West North Central 4.8 % 450 9.0 % 35,608 \0.001 4.8 % 368 5.0 % 380 0.632
New England 4.2 % 390 4.5 % 17,973 0.117 4.4 % 334 4.3 % 330 0.867




[0.33] (0.9) [0.18] (0.6) \0.001 [0.23] (0.7) [0.25] (0.7) 0.034
Chronic pulmonary disease 7.1 % 657 3.1 % 12,328 \0.001 5.3 % 406 5.4 % 412 0.827
Mild to moderate diabetes 4.4 % 411 4.0 % 15,747 0.030 3.7 % 280 4.4 % 335 0.022
Rheumatological disease 2.0 % 187 0.8 % 3,097 \0.001 1.3 % 99 1.4 % 106 0.614
Congestive heart failure 1.8 % 167 0.6 % 2,555 \0.001 1.0 % 76 1.2 % 93 0.180
Any malignancy, including
leukaemia and lymphoma
1.7 % 156 1.5 % 6,091 0.277 1.3 % 98 1.5 % 115 0.237
Cerebrovascular disease 1.7 % 155 0.6 % 2,513 \0.001 1.1 % 82 1.3 % 97 0.251
Diabetes with chronic
complications
1.4 % 127 0.8 % 3,138 \0.001 1.0 % 76 1.0 % 78 0.869
Peripheral vascular disease 1.3 % 122 0.5 % 1,914 \0.001 0.9 % 68 1.0 % 73 0.674
Mild liver disease 1.0 % 91 0.3 % 1,059 \0.001 0.7 % 52 0.7 % 50 0.843
Renal disease 0.9 % 82 0.4 % 1,588 \0.001 0.5 % 41 0.6 % 43 0.827
Peptic ulcer disease 0.6 % 52 0.1 % 542 \0.001 0.3 % 25 0.3 % 26 0.889
Myocardial infarction 0.4 % 38 0.2 % 660 \0.001 0.2 % 15 0.2 % 17 0.724
Hemiplegia or paraplegia 0.4 % 36 0.1 % 319 \0.001 0.2 % 17 0.2 % 15 0.724
Metastatic solid tumour 0.3 % 29 0.2 % 706 0.003 0.1 % 11 0.2 % 16 0.336
HIV/AIDS 0.3 % 27 0.2 % 622 0.001 0.2 % 17 0.2 % 14 0.590
Moderate or severe liver disease 0.1 % 13 0.0 % 91 \0.001 0.1 % 8 0.1 % 5 0.405




9.6 % 893 0.9 % 3,509 \0.001 5.5 % 422 5.1 % 392 0.222
Psychotic disorder 16.2 % 1,501 2.7 % 10,645 \0.001 11.0 % 845 10.8 % 824 0.552
Other mental disorder 27.7 % 2,572 7.2 % 28,645 \0.001 21.8 % 1,672 23.4 % 1,790 0.008
Healthcare resource use [mean] (SD)
Number of inpatient days [1.0] (5.1) [0.1] (1.7) \0.001 [0.3] (2.3) [0.3] (2.2) 0.716
Number of ED days [1.0] (3.5) [0.2] (1.1) \0.001 [0.5] (1.4) [0.4] (1.2) \0.001
Number of outpatient visits [8.3] (9.7) [3.7] (5.9) \0.001 [6.1] (7.4) [6.6] (8.2) \0.001
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above examined the excess costs of opioid abuse and
highlight the substantial burden imposed on employers,
including both direct healthcare costs and indirect work-
loss costs. We found that a diagnosed abuser had, on
average, excess annual healthcare costs of US$10,627 and
US$1,244 in excess annual work-loss costs. Although
previous papers have estimated the costs of opioid abuse, to
our knowledge this is the first study to assess excess costs
from the employer perspective using a refined set of con-
trols to account for significantly higher underlying rates of
comorbidities and baseline healthcare resource use. Efforts
to educate employees about warning signs of opioid abuse
may help employers reduce the burden of opioid abuse by
preventing opioid abuse or helping abusers to obtain
treatment sooner.
The excess PMPM healthcare costs of diagnosed opioid
abuse of US$1.65 represent substantial costs to employers
that are comparable to the costs of several costly mental
health conditions. For example, the excess PMPM health-
care costs of diagnosed opioid abuse are higher than the
published PMPM healthcare costs of schizophrenia
(US$0.30) and anxiety disorder (US$0.97), and are similar
to the PMPM healthcare costs of depression (US$1.73) and
alcoholism (US$2.00) [Table 4] [21].
While the excess costs of diagnosed opioid abuse
observed in claims data indicate a substantial burden to
employers, they nonetheless understate the overall costs of
opioid abuse to employers because they fail to account for
the large portion of opioid abusers who remain undiag-
nosed. A preliminary calculation suggests that the costs
associated with undiagnosed abuse may indeed exceed
those of diagnosed abuse. In order to obtain a preliminary
estimate of the prevalence of undiagnosed abuse, we
combined our claims data analyses of diagnosed abusers
with published government data from the NSDUH on the
overall rate of diagnosed and undiagnosed abuse in the
USA in 2011 (the most recent year for which a complete
year of claims data were available). In the absence of an
estimate of undiagnosed abuse in the literature, the dif-
ference between the overall rate of abuse reported in the
NSDUH (80 per 10,000) and the rate of diagnosed abuse
calculated in our claims data analysis (18.6 per 10,000)
provides a first approximation of the rate of undiagnosed
abuse in the USA (61.4 per 10,000) [6, 22, 23]. This rate of
undiagnosed abuse implies a ratio of 3.3 undiagnosed
abusers per diagnosed abuser in the USA.
Combining the preliminary prevalence estimates with
the estimated costs of undiagnosed abuse, which prior lit-
erature has estimated to be 80 % of the costs of diagnosed
abuse [15], suggests that undiagnosed opioid abuse may
contribute US$4.36 in additional excess PMPM healthcare
costs and US$0.16 in additional excess PMPM work-loss
costs. Excess PMPM healthcare costs of this magnitude
represent a substantial burden to employers and would be
comparable to published estimates of the PMPM healthcare
costs associated with colorectal cancer (US$4.38),
Table 1 continued
Unmatched sample Matched sampleb
Abusers Comparison
patients
p valuec Abusers Comparison
patients
p valued
% N % N % N % N
Number of rehabilitation
facility days
[0.3] (4.1) [0.0] (1.1) \0.001 [0.1] (2.2) [0.1] (1.9) 0.303
Number of other visits [1.2] (3.7) [0.5] (1.8) \0.001 [0.8] (2.4) [0.8] (2.1) 0.052
Number of prescriptions filled [17.4] (19.9) [5.4] (8.5) \0.001 [12.1] (13.6) [11.4] (14.1) \0.001
Number of unique NDCs fillede [7.9] (8.1) [2.9] (3.9) \0.001 [5.7] (5.7) [5.5] (5.9) \0.001
Total healthcare costsf [$8,418] ($25,390) [$2,129] ($9,503) \0.001 [$3,485] ($6,151) [$3,485] ($6,151) 0.510
AIDS acquired immune deficiency syndrome, ED emergency department, HIV human immunodeficiency virus, NDC National Drug Code,
SD standard deviation
a The baseline period was defined as the period between 12 months and 6 months prior to the index date
b Abusers were matched with potential comparison patients on the basis of the propensity score (within a quarter of a standard deviation), year of
the index date, availability of work-loss data (0/1) and total healthcare costs (within 10 %) during the baseline period
c p values were calculated using v2 tests for binary variables and Wilcoxon rank-sum tests for continuous variables
d p values were calculated using McNemar tests for matched pairs for binary variables and Wilcoxon signed-rank tests for continuous variables
e The numbers of unique NDCs filled were identified using 9-digit NDCs
f Healthcare costs were inflated to 2012 dollars, using the medical care component of the Consumer Price Index. The costs per patient reflect the
amount paid by the insurer, excluding out-of-pocket payments by patients (e.g. copay, deductibles). The numbers may not sum to the total,
because of rounding
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chronic obstructive pulmonary disease (US$5.35), obes-
ity (US$4.84–US$7.78) and osteoarthritis (US$6.64)
[Table 4] [21, 24]. Given the magnitude of potential costs
associated with undiagnosed abuse, further research should
attempt to validate the preliminary estimate of the preva-
lence of undiagnosed abuse, as well as the assumption that
the costs of undiagnosed abuse are 80 % of the costs of
diagnosed abuse.
This study had a number of limitations. First, the ana-
lysis relied on the accuracy of claims data to distinguish
abusers from comparison patients, evaluate their comor-
bidity profiles at baseline and evaluate healthcare resource
use and cost information during the follow-up period. Any
miscoding in the underlying data could have affected our
results, although we have no reason to believe that any
inaccuracies in the data affected the abusers or comparison
patients differently.
Second, and relatedly, because undiagnosed opioid
abusers do not receive any of the ICD-9-CM diagnosis
codes for abuse by definition, we expect that some of these
patients were actually included in our cohort of comparison
patients. While the extent to which this is the case is
unknown, if undiagnosed abusers are more costly than a
true comparison population comprising patients who are
not abusers, this would imply that the estimated excess
costs of diagnosed abuse understate the actual excess cost
differential between abusers and a comparison population
of patients without diagnosed or undiagnosed opioid abuse.
Third, the calculations of incremental healthcare and
work-loss costs were based on those of patients with
18 months of continuous eligibility. This requirement was
necessary in order to ensure complete visibility of medical
and prescription drug claims during the study period.
However, this criterion could have excluded more severe
abusers, who may be less capable of maintaining constant
employment and health insurance eligibility. This would
imply that our estimates of the burden of opioid abuse are
an underestimate.
Table 2 Healthcare resource use and costs among matched abusers (N = 7,658) and comparison patients (N = 7,658) in the follow-up perioda,b
Abusers Comparison patients Difference Ratio p valuec
Mean SD Mean SD
Healthcare resource use
Medical resource use
Number of inpatient days 4.5 11.0 0.9 5.6 3.6 4.9 \0.001
Number of ED days 2.5 4.7 0.8 2.4 1.7 3.1 \0.001
Number of outpatient visits 19.7 17.3 14.4 15.6 5.3 1.4 \0.001
Number of rehabilitation facility days 6.5 19.2 0.2 2.9 6.2 31.2 \0.001
Number of other visits 3.1 6.4 1.9 5.5 1.1 1.6 \0.001
Prescription drug use
Number of prescriptions filled 31.6 30.6 22.4 27.7 9.2 1.4 \0.001
Number of unique NDCs filledd 13.3 12.8 8.5 8.8 4.8 1.6 \0.001
Healthcare costse
Total healthcare costs $20,343 $36,498 $9,716 $26,676 $10,627 2.1 \0.001
Medical costs $17,518 $35,488 $7,671 $25,639 $9,847 2.3 \0.001
Inpatient costs $5,843 $25,952 $2,345 $18,932 $3,498 2.5 \0.001
ED costs $3,163 $9,880 $871 $5,232 $2,291 3.6 \0.001
Outpatient costs $5,465 $10,532 $3,997 $11,483 $1,467 1.4 \0.001
Rehabilitation facility costs $1,821 $5,904 $49 $825 $1,772 36.9 \0.001
Other costs $1,227 $4,681 $408 $4,541 $819 3.0 \0.001
Prescription drug costs $2,826 $5,169 $2,045 $4,287 $781 1.4 \0.001
ED emergency department, NDC National Drug Code, SD standard deviation
a The 12-month follow-up period was defined as the 6 months prior to and the 6 months following the index date. The numbers may not sum to
the total, because of rounding
b Abusers were matched with potential comparison patients on the basis of the propensity score (within a quarter of a standard deviation), year of
the index date, availability of work loss data (0/1) and total healthcare costs (within 10 %) during the baseline period
c p values were calculated using McNemar tests for matched pairs for binary variables and Wilcoxon signed-rank tests for continuous variables
d The numbers of unique NDCs filled were identified using 9-digit NDCs
e Healthcare costs were inflated to 2012 US dollars, using the medical care component of the Consumer Price Index. The costs per patient reflect
the amount paid by the insurer, excluding out-of-pocket payments by patients (e.g. copay, deductibles)
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Fourth, while propensity score matching led to matched
cohorts having similar baseline characteristics, approxi-
mately 20 % of abusers were excluded. These included
some high-cost patients with higher rates of comorbidities
and medical resource use from the analysis (Table 1),
possibly suggesting that the estimate of excess costs was
conservative.
Fifth, the analysis did not include certain cost cate-
gories that are relevant to employers, including sick time
spent at home (i.e. the analysis only accounted for time
lost because of healthcare visits), reduced on-the-
job productivity or costs associated with potential turn-
over of some individuals (e.g. administrative costs of
identifying and training new employees). Also, the work-
loss estimates were based on an algorithm that calcu-
lates days missed as a function of medical resource
utilization, and we did not observe the extent to which
certain employees may have compensated for medically
related absenteeism (e.g. by working on weekends). As a
result, the actual indirect work-loss costs of opioid
abuse borne by employers may differ from those repor-
ted here. Finally, we assumed that the prevalence and
costs of diagnosed abuse calculated in the OptumHealth
claims data were representative of the prevalence and
costs of diagnosed abuse of the broader population
covered by self-insured employers. Future research
should validate these findings in other commercial claims
databases.
Table 3 Medically related absenteeism, disability and related costs among matched abusers (N = 1,162) and comparison patients (N = 1,162)
in the follow-up perioda,b
Abusers Comparison patients Difference Ratio p valuec
Mean SD Mean SD
Work loss
Patients with any work-loss day [%] (n) [99.9 %] (1,161) [99.1 %] (1,152) [0.8 %] 1.0 0.007
Patients with disability [16.6 %] (193) [12.0 %] (139) [4.6 %] 1.4 0.001
Patients with medically related absenteeismd [96.5 %] (1,121) [97.8 %] (1,137) [-1.4 %] 1.0 0.046
Number of work-loss days 28.9 52.5 15.6 36.7 13.3 1.8 \0.001
Number of disability days 15.5 51.7 9.2 36.3 6.3 1.7 0.002
Number of medically related absenteeism days 13.4 19.3 6.4 7.2 7.0 2.1 \0.001
Work-loss costse,f
Total work-loss costs $3,773 $6,648 $2,528 $4,612 $1,244 1.5 \0.001
Disability costs $1,378 $5,347 $873 $3,600 $505 1.6 0.007
Medically related absenteeism costs $2,395 $4,305 $1,655 $2,840 $739 1.4 \0.001
ED emergency department, SD standard deviation
a The 12-month follow-up period was defined as the 6 months prior to and the 6 months following the index date. The numbers may not sum to
the total, because of rounding
b Abusers were matched with potential comparison patients on the basis of the propensity score (within a quarter of a standard deviation), year of
the index date, availability of work loss data (0/1) and total healthcare costs (within 10 %) during the baseline period
c p values were calculated using McNemar tests for matched pairs for binary variables and Wilcoxon signed-rank tests for continuous variables
d Medically related absenteeism was calculated using medical claims occurring during the work week. Days with a hospitalization or ED visit
were counted as a full day of absenteeism, and all other visits were counted as a half day of absenteeism, following Birnbaum et al. [8]
e Disability costs were obtained directly from the database. Medically related absenteeism costs were calculated by multiplying the number of
days of missed work by the employee’s daily wage
f Total work-loss costs were inflated to 2012 US dollars, using the all-items component of the Consumer Price Index







$0.30 Goetzel et al. [21]
Anxiety disorder $0.97 Goetzel et al. [21]
Opioid abuse
(diagnosed)
$1.65 Authors’ calculation based on
OptumHealth Reporting and
Insights claims data analysis
Depression $1.73 Goetzel et al. [21]
Alcoholism $2.00 Goetzel et al. [21]
Colorectal cancer $4.38 Goetzel et al. [21]
Obesity (in men) $4.84 Long et al. [24]
Chronic obstructive
pulmonary disease
$5.35 Goetzel et al. [21]
Obesity (in women) $7.78 Long et al. [24]
Osteoarthritis $6.64 Goetzel et al. [21]
Hypertension $13.15 Goetzel et al. [21]
a All costs were inflated to 2012 US dollars, using the medical care
services component of the Consumer Price Index (December figures)
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5 Conclusion
This study has provided an up-to-date and refined estimate
of the annual incremental costs of diagnosed opioid abuse,
using a large administrative claims database, controlling
for a broad array of underlying differences between opioid
abusers and comparison patients. Many payers in the
healthcare industry are unaware of the substantial burden
of prescription opioid abuse [25]. However, our study has
demonstrated that there are substantial costs of abuse to
employers, who pay for a large portion of the healthcare
costs of opioid abusers. Employers also incur costs of work
loss and diminished workplace productivity due to opioid
abuse. These results suggest that in addition to recent and
widespread government and regulatory initiatives in this
therapeutic area, it may be beneficial for employers, for
whom the full burden of opioid abuse is potentially hidden,
to take proactive steps to address the issue through edu-
cational programmes on the warning signs of opioid abuse
and coverage of broad options for treatment.
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Technical Appendix
As discussed above, propensity score matching was used to
account for observable differences at baseline between
abusers and comparison patients. Specifically, a logistic
regression model was used, with the dependent variable
being an indicator of whether a patient was diagnosed with
opioid abuse or dependence. Independent variables inclu-
ded the following patients and baseline characteristics:
• Age (years)
• Sex indicator
• Indicators for US Census Divisions
• Indicator variables for diagnoses of selected baseline
comorbidities
• Myocardial infarction; congestive heart failure;
peripheral vascular disease; cerebrovascular
Table 5 Propensity score logistic regression model results
Parameter Coefficient SE p value
Intercept -5.23 0.47 \0.001
Demographic characteristics
Age -0.03 0.00 \0.001
Male sex -0.32 0.01 \0.001
US Census Division
Unknown -1.10 0.29 \0.001
1: New England 0.11 0.06 0.064
2: Middle Atlantic 0.47 0.04 \0.001
3: East North Central 0.21 0.04 \0.001
4: West North Central -0.54 0.06 \0.001
5: South Atlantic 0.10 0.04 0.013
6: East South Central 0.34 0.05 \0.001
7: West South Central -0.13 0.05 0.004
8: Mountain 0.45 0.05 \0.001
Comorbidities
Chronic pulmonary disease 0.11 0.02 \0.001
Mild to moderate diabetes 0.40 0.03 \0.001
Rheumatological disease 0.04 0.05 0.344




Cerebrovascular disease 0.02 0.05 0.722
Diabetes with chronic complications 0.55 0.06 \0.001
Peripheral vascular disease -0.03 0.06 0.591
Mild liver disease -0.21 0.07 0.001
Renal disease 0.31 0.07 \0.001
Peptic ulcer disease -0.10 0.09 0.298
Myocardial infarction 0.24 0.11 0.022
Hemiplegia or paraplegia -0.09 0.11 0.421
Metastatic solid tumour 0.20 0.11 0.073
HIV/AIDS 0.30 0.11 0.007
Moderate or severe liver disease -0.02 0.20 0.900




Psychotic disorder -0.27 0.02 \0.001
Other mental disorder -0.36 0.01 \0.001
Baseline healthcare resource use
Inpatient days 0.01 0.00 0.001
ED days 0.05 0.00 \0.001
Outpatient visits 0.01 0.00 \0.001
Rehabilitation facility days 0.01 0.00 0.064
Other visits -0.02 0.00 \0.001
Number of prescriptions filled 0.04 0.00 \0.001
Number of unique NDCs filled 0.07 0.00 \0.001
The sample size was 405,192
AIDS acquired immune deficiency syndrome, ED emergency
department, HIV human immunodeficiency virus, NDC National
Drug Code, SE standard error
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disease; dementia; chronic pulmonary disease;
rheumatological disease; peptic ulcer disease; mild
liver disease; mild to moderate diabetes; diabetes
with chronic complications; hemiplegia or paraple-
gia; renal disease; any malignancy, including leu-
kaemia and lymphoma; moderate or severe liver
disease; metastatic solid tumour; HIV/AIDS; psy-
chotic disorders; non-opioid substance abuse diag-
noses; other mental disorders
• Baseline healthcare resource utilization
• Number of inpatient days; number of ED days;
number of outpatient visits; number of rehabilita-
tion facility days; number of other visits
• Number of unique NDCs filled; number of pre-
scriptions filled
Appendix Table 5 summarizes the results of the logistic
regression model used to estimate the propensity scores.
The model yielded a c-statistic of 0.81. Following pro-
pensity score estimation, abusers were matched one-to-one
with comparison patients on the basis of the year of the
index date, baseline healthcare costs (±10 %), availability
of work-loss data and propensity score (within a quarter of
a standard deviation), using greedy matching. The year of
the index date was meant to account for possible differ-
ences over time in treatment practices. Baseline healthcare
costs were used as a measure of severity to ensure that
there were no underlying differences in the intensity of
healthcare resource use at baseline. Inclusion of baseline
healthcare costs in the propensity score model was exam-
ined and was found to result in a poorer match at baseline
and greater study period excess costs of abuse. The avail-
ability of work-loss data was important to include in the
direct match to allow for consistent examination of the
subset of patients with work-loss data.
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